Vasodilator monotherapy in the treatment of hypertension: Comparative efficacy and safety of pinacidil, a potassium channel opener, and prazosin
- 1 July 1988
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 44 (1) , 78-92
- https://doi.org/10.1038/clpt.1988.117
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Antihypertensive treatment with metoprolol or hydrochlorothiazide in patients aged 60 to 75 years. Report from a double-blind international multicenter studyJAMA, 1986
- Comparison of the effects of pinacidil and its metabolite, pinacidil-N-oxide, in isolated smooth and cardiac muscleDrug Development Research, 1986
- Pharmacokinetics and Bioavailability of Pinacidil Capsules in Human VolunteersJournal of International Medical Research, 1985
- Acute hemodynamic effects of pinacidil and hydralazine in essential hypertensionClinical Pharmacology & Therapeutics, 1985
- SYSTEMIC AND CORONARY HEMODYNAMIC-EFFECTS OF PINACIDIL, A NEW ANTIHYPERTENSIVE AGENT, IN AWAKE DOGS - COMPARISON WITH HYDRALAZINE1985
- Pinacidil, a new vasodilator, in the treatment of mild to moderate essential hypertensionEuropean Journal of Clinical Pharmacology, 1985
- Treatment of essential hypertension and hypertension associated with renal impairment with pinacidil: A new vasodilatorEuropean Journal of Clinical Pharmacology, 1985
- Pinacidil, a new vasodilator, in the treatment of patients with moderate to severe hypertensionEuropean Journal of Clinical Pharmacology, 1984
- Treatment of mild hypertension: A five year controlled drug trialThe American Journal of Medicine, 1980